BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

753 related articles for article (PubMed ID: 31307035)

  • 21. Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis.
    Kaneko S; Tsuchiya K; Yasui Y; Inada K; Kirino S; Yamashita K; Osawa L; Hayakawa Y; Sekiguchi S; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Takeguchi T; Takeguchi Y; Nagano T; Nakanishi H; Itakura J; Takahashi Y; Himeno Y; Hoshi A; Kurosaki M; Izumi N
    Hepatol Res; 2020 Dec; 50(12):1375-1385. PubMed ID: 32924266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors Raising Serum Ammonia Level During Lenvatinib Treatment of Patients With Hepatocellular Carcinoma.
    Narita R; Kotoh K; Yoneda A; Motomura M; Harada M
    Anticancer Res; 2020 Sep; 40(9):5271-5276. PubMed ID: 32878816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma.
    Hiraoka A; Kumada T; Michitaka K; Toyoda H; Tada T; Ueki H; Kaneto M; Aibiki T; Okudaira T; Kawakami T; Kawamura T; Yamago H; Suga Y; Miyamoto Y; Tomida H; Azemoto N; Mori K; Miyata H; Ninomiya T; Kawasaki H
    J Gastroenterol Hepatol; 2016 May; 31(5):1031-6. PubMed ID: 26647219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liver Function Assessment Using Albumin-Bilirubin Grade for Patients with Very Early-Stage Hepatocellular Carcinoma Treated with Radiofrequency Ablation.
    Oh IS; Sinn DH; Kang TW; Lee MW; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Dig Dis Sci; 2017 Nov; 62(11):3235-3242. PubMed ID: 28983724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma.
    Yukimoto A; Hirooka M; Hiraoka A; Michitaka K; Ochi H; Joko K; Imai Y; Watanabe T; Koizumi Y; Yoshida O; Abe M; Hiasa Y
    Jpn J Clin Oncol; 2019 Jan; 49(1):42-47. PubMed ID: 30380075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.
    Edeline J; Blanc JF; Campillo-Gimenez B; Ma YT; King J; Faluyi O; Mathurin J; Ghazi S; Palmer DH; Meyer T
    Eur J Cancer; 2017 Nov; 86():135-142. PubMed ID: 28987770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current Roles of Ramucirumab in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
    Koizumi A; Komatsu S; Omiya S; Yano Y; Fujishima Y; Ishida J; Kido M; Gon H; Fukushima K; Urade T; So S; Yoshida T; Arai K; Fujinaka R; Shimura Y; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
    Anticancer Res; 2024 May; 44(5):2055-2061. PubMed ID: 38677746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Easy clinical predictor for low BCAA to tyrosine ratio in chronic liver disease patients with hepatocellular carcinoma: Usefulness of ALBI score as nutritional prognostic marker.
    Hiraoka A; Kato M; Marui K; Murakami T; Onishi K; Adachi T; Matsuoka J; Ueki H; Yoshino T; Tsuruta M; Aibiki T; Okudaira T; Kuroda T; Iwasaki R; Suga Y; Miyata H; Ninomiya T; Hirooka M; Abe M; Matsuura B; Michitaka K; Hiasa Y
    Cancer Med; 2021 Jun; 10(11):3584-3592. PubMed ID: 33960691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
    Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
    Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA.
    Singal AG; Nagar SP; Hitchens A; Davis KL; Iyer S
    Future Oncol; 2021 Jul; 17(21):2759-2768. PubMed ID: 33832339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential therapy including regorafenib for unresectable hepatocellular carcinoma: Effect of early relative changes in hepatic functional reserve after regorafenib administration on prognosis.
    Ochi H; Tani J; Tomonari T; Taniguchi T; Koizumi Y; Hirose A; Ogawa C; Hiraoka A; Morishita A; Moriya A; Hirooka M; Deguchi A; Symple Study Group
    Hepatol Res; 2021 Dec; 51(12):1219-1228. PubMed ID: 34534398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
    Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
    J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a thrombus in the superior mesenteric artery associated with sequential therapy with tyrosine kinase inhibitors for hepatocellular carcinoma.
    Nawa T; Katayama K; Kiyota R; Imai T; Abe Y; Hasegawa N; Takada R; Fukutake N; Ikezawa K; Sakakibara M; Fujita M; Ohkawa K
    Clin J Gastroenterol; 2020 Apr; 13(2):247-251. PubMed ID: 31317371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting.
    Hiraoka A; Kumada T; Kariyama K; Tada T; Tani J; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Yasuda S; Toyoda H; Ohama H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Michitaka K; Hiasa Y; Kudo M;
    J Gastroenterol Hepatol; 2021 Jul; 36(7):1812-1819. PubMed ID: 33171524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases.
    Izumoto H; Hiraoka A; Ishimaru Y; Murakami T; Kitahata S; Ueki H; Aibiki T; Okudaira T; Miyamoto Y; Yamago H; Iwasaki R; Tomida H; Mori K; Kishida M; Tsubouchi E; Miyata H; Ninomiya T; Kawasaki H; Hirooka M; Matsuura B; Abe M; Hiasa Y; Michitaka K; Kudo M
    Oncology; 2017; 93 Suppl 1():120-126. PubMed ID: 29258105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
    Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
    Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?
    Hiraoka A; Kumada T; Tada T; Kariyama K; Tani J; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Yasuda S; Toyoda H; Ohama H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Michitaka K; Hiasa Y; Kudo M
    Liver Cancer; 2021 Apr; 10(2):115-125. PubMed ID: 33977088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma.
    Edeline J; Blanc JF; Johnson P; Campillo-Gimenez B; Ross P; Ma YT; King J; Hubner RA; Sumpter K; Darby S; Evans J; Iwuji C; Swinson D; Collins P; Patel K; Muazzam I; Palmer DH; Meyer T
    Liver Int; 2016 Dec; 36(12):1821-1828. PubMed ID: 27214151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic.
    Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Michitaka K; Deguchi A; Ishikawa T; Imai M; Ochi H; Joko K; Shimada N; Tajiri K; Hirooka M; Koizumi Y; Hiasa Y; Tanaka J
    J Gastroenterol Hepatol; 2019 Jun; 34(6):1066-1073. PubMed ID: 30549320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma.
    Kirino S; Tsuchiya K; Kurosaki M; Kaneko S; Inada K; Yamashita K; Osawa L; Hayakawa Y; Sekiguchi S; Okada M; Wang W; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Izumi N
    PLoS One; 2020; 15(4):e0231828. PubMed ID: 32310967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.